Neomorphic

Neomorph is a biotechnology company focused on the discovery and development of novel small molecule therapeutics, specifically molecular glues. The company's platform aims to solve the "undruggable" challenge by inducing new interactions between E3 ubiquitin ligases and target proteins to trigger their degradation. Founded in 2020 and based in San Diego, Neomorph targets high-value proteins in oncology and rare diseases that have traditionally been inaccessible to conventional drug discovery methods. In 2024, the company entered a significant strategic collaboration with Novo Nordisk to develop molecular glue degraders for cardiometabolic and rare diseases. Backed by top-tier investors like Novo Holdings and NEA, Neomorph is led by pioneers in the field of targeted protein degradation.